A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates

Other illness

• Patients with malignant or severe hypertension (systolic blood pressure \[SBP\] ≥180 mmHg, diastolic blood pressure \[DBP\] ≥110 mmHg) at baseline.
• Patients with secondary causes of hypertension, as determined by the treating physician.
• Patients with a history of, or at risk of developing, angioedema.

Lab values

• Patients with evidence of severe renal impairment (e.g., estimated glomerular filtration rate \[eGFR\] \<30 mL/min/1.73 m\^2).
• Patients with serum potassium level ≥5.5 mmol/L at baseline.

Other

• Pregnant or lactating women.

• Adult male or female patients (≥18 years).
• Patients with physician-diagnosed hypertension (as defined by international guidelines including the American Heart Association/American College of Cardiology \[AHA/ACC\] guidelines and/or the 2024 European Society of Cardiology \[ESC\] guidelines).
• Patients with documented office blood pressure ≥130/80 mmHg prior to initiating treatment (ARNi or monotherapy) or transitioning from monotherapy to ARNi.
• Patients who are either antihypertensive therapy naïve or currently receiving antihypertensive monotherapy (ACE inhibitor/ARB/CCB) with a physician-directed requirement to transition to ARNi.
  • Note: Patients who transition from one monotherapy to another during the study are not eligible for inclusion.
• Patients willing to provide written informed consent to participate in the study.